Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Affibody-mediated retention of the epidermal growth factor receptor in the secretory compartments leads to inhibition of phosphorylation in the kinase domain
KTH, School of Biotechnology (BIO), Molecular Biotechnology.
KTH, School of Biotechnology (BIO), Molecular Biotechnology.ORCID iD: 0000-0001-7034-0850
KTH, School of Biotechnology (BIO), Molecular Biotechnology.
KTH, School of Biotechnology (BIO), Molecular Biotechnology.
Show others and affiliations
2009 (English)In: New biotechnology, ISSN 1871-6784, Vol. 25, no 6, 417-423 p.Article in journal (Refereed) Published
Abstract [en]

Abnormal activity of the epidermal growth factor receptor (EGFR) is associated with various cancer-related processes and motivates the search for strategies that can selectively block EGFR signalling. In this study, functional knockdown of EGFR was achieved through expression of an affibody construct, (Z(EGFR:1907))(2)-KDEL, with high affinity for EGFR and extended with the amino acids KDEL to make it resident in the secretory compartments. Expression of (Z(EGFR:1907))(2)-KDEL resulted in 80% reduction of the cell surface level of EGFR, and fluorescent staining for EGFR and the (Z(EGFR:1907))(2)-KDEL construct showed overlapping intracellular localisation. Immunocapture of EGFR from cell lysates showed that an intracellular complex between EGFR and the affibody construct had been formed, further indicating a specific interaction between the affibody construct and EGFR. Surface depletion of EGFR led to a dramatic decrease in the amount of kinase domain phosphorylated EGFR, coincident with a significant decrease in the proliferation rate.

Place, publisher, year, edition, pages
2009. Vol. 25, no 6, 417-423 p.
Keyword [en]
neu differentiation factor; intracellular antibodies; tumor-cells; erbb receptors; in-vivo; affinity; cancer; activation; molecule; requirement
National Category
Industrial Biotechnology
Identifiers
URN: urn:nbn:se:kth:diva-10076DOI: 10.1016/j.nbt.2009.02.001ISI: 000270772100009Scopus ID: 2-s2.0-70449523599OAI: oai:DiVA.org:kth-10076DiVA: diva2:207404
Note
QC 20100813Available from: 2009-03-11 Created: 2009-03-11 Last updated: 2010-12-07Bibliographically approved
In thesis
1. Affinity protein based inhibition of cancer related signaling pathways
Open this publication in new window or tab >>Affinity protein based inhibition of cancer related signaling pathways
2009 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Dysregulation of protein activity, caused by alterations in protein sequence, expression, or localization, is associated with numerous diseases. In order to control the activity of harmful protein entities, affinity ligands such as proteins, oligonucleotides or small molecules can be engineered to specifically interact with them to modulate their function. In this thesis, non-immunoglobulin based affinity proteins known as affibody molecules are used to functionally inhibit proteins important for signaling through pathways that are overactive in different cancers.

 

In Paper I and Paper II, affibody molecules with high affinity for the receptor tyrosine kinases HER2 or EGFR are expressed in the secretory compartments of model cancer cell lines SKOV3 or A431 using a retrovirus-based gene delivery system. Equipping the affinity proteins with an ER retention tag, the affibody molecules together with their target protein are retained in the secretory compartments as shown by confocal fluorescence imaging. Flow cytometric analysis showed a 60 % or 80 % downregulation of surface located HER2 or EGFR in these cell lines, respectively. A significant decreased in proliferation rate of the cells was also observed, which for EGFR retention could be correlated with inhibition of phosphorylation in the kinase domain. In Paper III, novel affibody molecules interacting with the hormone binding site of the insulin growth factor-1 receptor were generated. One variant had high (1.2 nM) affinity for the receptor and could be used for immunofluorescence analysis and for receptor pull-out from cell lysates. Addition of this affibody molecule to MCF-7 cells had a dose dependent growth inhibitory effect on the cells. In Paper IV, novel affibody molecules against the intracellular oncoproteins H-Ras and Raf-1 were selected and characterized, and they proved to be specific for their target proteins. Mapping experiments showed that the affibody molecules selected against H-Ras interacted at over-lapping epitopes not affecting the interaction between Ras and Raf. In contrast, the predominant variant isolated during selection against Raf-1 could completely inhibit the Ras/Raf interaction in a real-time biospecific interaction analysis.

 

Taken together, the affibody molecules presented here and the strategies by which they are used to interfere with cancer related proteins and pathways may be valuable tools for further investigation of these systems and may possibly also be used to generate molecules suitable for cancer therapy.

Place, publisher, year, edition, pages
Stockholm: KTH, 2009. xii, 67 p.
Series
Trita-BIO-Report, ISSN 1654-2312 ; 2009:01
Keyword
Affibody, cancer, endoplasmic reticulum retention, EGFR, HER2, IGF-1R, Raf, Ras
National Category
Industrial Biotechnology
Identifiers
urn:nbn:se:kth:diva-10041 (URN)978-91-7415-232-6 (ISBN)
Public defence
2009-03-20, K1, KTH, Teknikringen 56, Stockholm, 10:00 (English)
Opponent
Supervisors
Note
QC 20100818Available from: 2009-03-11 Created: 2009-03-06 Last updated: 2010-08-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textScopushttp://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B8JG4-4VKXCBJ-2&_user=4478132&_coverDate=02%2F13%2F2009&_alid=881407084&_rdoc=1&_fmt=high&_orig=search&_cdi=43660&_sort=d&_docanchor=&view=c&_ct=1&_acct=C000034958&_version=1&_urlVersion=0&_userid=4478132&md5=5a6adb2b639c73c7bfc54755470786a8

Authority records BETA

Lundberg, EmmaNygren, Per-ÅkeGräslund, Torbjörn

Search in DiVA

By author/editor
Vernet, ErikLundberg, EmmaFriedman, MikaelaRigamonti, NicolòKlausing, SandraNygren, Per-ÅkeGräslund, Torbjörn
By organisation
Molecular Biotechnology
Industrial Biotechnology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 53 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf